Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias?

Tanner EJ, Chi DS, Eisenhauer EL, Diaz-Montes TP, Santillan A, Bristow RE.

Gynecol Oncol. 2010 May;117(2):336-40. doi: 10.1016/j.ygyno.2010.01.014. Epub 2010 Feb 12.

PMID:
20153027
2.

The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer.

Rocconi RP, Matthews KS, Kemper MK, Hoskins KE, Huh WK, Straughn JM Jr.

Gynecol Oncol. 2009 Aug;114(2):242-5. doi: 10.1016/j.ygyno.2009.04.019. Epub 2009 May 17.

PMID:
19447480
3.

[Impact of neoadjuvant chemotherapy on the survival of patients with stage IIIc and IV epithelial ovarian cancer].

Yan X, An N, Jiang GQ, Gao M, Gao YN.

Zhonghua Zhong Liu Za Zhi. 2008 Apr;30(4):298-301. Chinese.

PMID:
18788637
4.

Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome.

Karam AK, Santillan A, Bristow RE, Giuntoli R 2nd, Gardner GJ, Cass I, Karlan BY, Li AJ.

Gynecol Oncol. 2007 Feb;104(2):377-80. Epub 2006 Oct 2.

PMID:
17014899
5.

Surgical cytoreduction for recurrent epithelial ovarian cancer.

Al Rawahi T, Lopes AD, Bristow RE, Bryant A, Elattar A, Chattopadhyay S, Galaal K.

Cochrane Database Syst Rev. 2013 Feb 28;(2):CD008765. doi: 10.1002/14651858.CD008765.pub3. Review.

PMID:
23450588
6.

Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy.

Eisenhauer EL, Tew WP, Levine DA, Lichtman SM, Brown CL, Aghajanian C, Huh J, Barakat RR, Chi DS.

Gynecol Oncol. 2007 Aug;106(2):381-7. Epub 2007 May 16.

PMID:
17509673
7.

Timing and patterns of recurrence in epithelial ovarian cancer patients with no gross residual disease after primary debulking surgery.

Paik ES, Lee YY, Shim M, Choi HJ, Kim TJ, Choi CH, Lee JW, Kim BG, Bae DS.

Aust N Z J Obstet Gynaecol. 2016 Dec;56(6):639-647. doi: 10.1111/ajo.12529. Epub 2016 Sep 9.

PMID:
27611447
8.

Platinum resistance and impaired survival in patients with advanced primary peritoneal carcinoma: matched-case comparison with patients with epithelial ovarian carcinoma.

Eisenhauer EL, Sonoda Y, Levine DA, Abu-Rustum NR, Gemignani ML, Sabbatini PJ, Barakat RR, Chi DS.

Am J Obstet Gynecol. 2008 Feb;198(2):213.e1-7. doi: 10.1016/j.ajog.2007.07.003.

PMID:
18226627
9.

[Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].

Ma Y, Li Y, Cui H, Liang XD, Tang ZJ, Li XP, Zhao Y, Wei LH.

Zhonghua Fu Chan Ke Za Zhi. 2012 May;47(5):355-60. Chinese.

PMID:
22883524
10.

Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy.

Nishio S, Katsumata N, Matsumoto K, Tanabe H, Yonemori K, Kouno T, Shimizu C, Ando M, Kamura T, Kasamatsu T, Fujiwara Y.

J Cancer Res Clin Oncol. 2009 Apr;135(4):551-7. doi: 10.1007/s00432-008-0488-x. Epub 2008 Oct 1.

PMID:
18830625
11.

The effect of hospital operative volume, residual tumor and first-line chemotherapy on survival of ovarian cancer - a prospective nation-wide study in Finland.

Kumpulainen S, Sankila R, Leminen A, Kuoppala T, Komulainen M, Puistola U, Hurme S, Hiekkanen H, Mäkinen J, Grénman S.

Gynecol Oncol. 2009 Nov;115(2):199-203. doi: 10.1016/j.ygyno.2009.07.011. Epub 2009 Aug 19.

PMID:
19695688
12.

Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.

Skaznik-Wikiel ME, Lesnock JL, McBee WC, Beriwal S, Zorn KK, Richard SD, Krivak TC, Edwards RP.

Int J Gynecol Cancer. 2012 Feb;22(2):232-7. doi: 10.1097/IGC.0b013e318234f833.

PMID:
22080886
13.

The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer.

Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Aghajanian C, Barakat RR, Chi DS.

Gynecol Oncol. 2008 Feb;108(2):276-81. Epub 2007 Dec 11.

PMID:
18063020
14.

The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC).

Cheng X, Jiang R, Li ZT, Tang J, Cai SM, Zhang ZY, Tian WJ, Zang RY.

Eur J Surg Oncol. 2009 Oct;35(10):1105-8. doi: 10.1016/j.ejso.2009.03.010. Epub 2009 May 13.

PMID:
19443175
15.

Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer.

Zang RY, Zhang ZY, Li ZT, Chen J, Tang MQ, Liu Q, Cai SM.

J Surg Oncol. 2000 Sep;75(1):24-30.

PMID:
11025458
16.

Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.

Esselen KM, Rodriguez N, Growdon W, Krasner C, Horowitz NS, Campos S.

Gynecol Oncol. 2012 Oct;127(1):51-4. doi: 10.1016/j.ygyno.2012.05.026. Epub 2012 May 30.

PMID:
22659193
17.

Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: a multicenter study.

Ferrero A, Ditto A, Giorda G, Gadducci A, Greggi S, Daniele A, Fuso L, Panuccio E, Scaffa C, Raspagliesi F, Sismondi P, Biglia N.

Eur J Surg Oncol. 2014 Jul;40(7):891-8. doi: 10.1016/j.ejso.2013.11.026. Epub 2013 Dec 14.

PMID:
24378007
18.

Outcomes and patterns of secondary relapse in platinum-sensitive ovarian cancer: implications for tertiary cytoreductive surgery.

Tang J, Liu DL, Shu S, Tian WJ, Liu Y, Zang RY.

Eur J Surg Oncol. 2013 Jul;39(7):786-91. doi: 10.1016/j.ejso.2013.02.006. Epub 2013 Mar 13.

PMID:
23490332
19.

Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.

Landrum LM, Moore KN, Myers TK, Lanneau GS Jr, McMeekin DS, Walker JL, Gold MA.

Gynecol Oncol. 2009 Feb;112(2):337-41. doi: 10.1016/j.ygyno.2008.10.009. Epub 2008 Nov 28.

PMID:
19041126

Supplemental Content

Support Center